Expression of programmed cell death-1 on neuroblastoma cells in TH-MYCN transgenic mice

Zurück zum Zitat Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202–2211CrossRefPubMedPubMedCentral Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202–2211CrossRefPubMedPubMedCentral

Zurück zum Zitat Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE (2017) Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther 17(4):369–386CrossRefPubMed Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE (2017) Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther 17(4):369–386CrossRefPubMed

Zurück zum Zitat Newman EA, Nuchtern JG (2016) Recent biologic and genetic advances in neuroblastoma: implications for diagnostic, risk stratification, and treatment strategies. Semin Pediatr Surg 25(5):257–264CrossRefPubMed Newman EA, Nuchtern JG (2016) Recent biologic and genetic advances in neuroblastoma: implications for diagnostic, risk stratification, and treatment strategies. Semin Pediatr Surg 25(5):257–264CrossRefPubMed

Zurück zum Zitat Morandi F, Sabatini F, Podesta M, Airoldi I (2021) Immunotherapeutic strategies for neuroblastoma: present past and future. Vaccines (Basel) 9(1):43CrossRefPubMed Morandi F, Sabatini F, Podesta M, Airoldi I (2021) Immunotherapeutic strategies for neuroblastoma: present past and future. Vaccines (Basel) 9(1):43CrossRefPubMed

Zurück zum Zitat Furman WL (2021) Monoclonal antibody therapies for high risk neuroblastoma. Biologics 15:205–219PubMedPubMedCentral Furman WL (2021) Monoclonal antibody therapies for high risk neuroblastoma. Biologics 15:205–219PubMedPubMedCentral

Zurück zum Zitat Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203(4):883–895CrossRefPubMedPubMedCentral Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203(4):883–895CrossRefPubMedPubMedCentral

Zurück zum Zitat Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974–1982CrossRefPubMedPubMedCentral Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974–1982CrossRefPubMedPubMedCentral

Zurück zum Zitat Webb ER, Lanati S, Wareham C, Easton A, Dunn SN, Inzhelevskaya T, Sadler FM, James S, Ashton-Key M, Cragg MS, Beers SA, Gray JC (2020) Immune characterization of pre-clinical murine models of neuroblastoma. Sci Rep 10(1):16695CrossRefPubMedPubMedCentral Webb ER, Lanati S, Wareham C, Easton A, Dunn SN, Inzhelevskaya T, Sadler FM, James S, Ashton-Key M, Cragg MS, Beers SA, Gray JC (2020) Immune characterization of pre-clinical murine models of neuroblastoma. Sci Rep 10(1):16695CrossRefPubMedPubMedCentral

Zurück zum Zitat Eissler N, Mao Y, Brodin D, Reutersward P, Andersson Svahn H, Johnsen JI, Kiessling R, Kogner P (2016) Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. Oncoimmunology 5(12):e1232222CrossRefPubMedPubMedCentral Eissler N, Mao Y, Brodin D, Reutersward P, Andersson Svahn H, Johnsen JI, Kiessling R, Kogner P (2016) Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. Oncoimmunology 5(12):e1232222CrossRefPubMedPubMedCentral

Zurück zum Zitat Ardavin C (2003) Origin, precursors and differentiation of mouse dendritic cells. Nat Rev Immunol 3(7):582–590CrossRefPubMed Ardavin C (2003) Origin, precursors and differentiation of mouse dendritic cells. Nat Rev Immunol 3(7):582–590CrossRefPubMed

Zurück zum Zitat Asselin-Paturel C, Brizard G, Pin JJ, Briere F, Trinchieri G (2003) Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol 171(12):6466–6477CrossRefPubMed Asselin-Paturel C, Brizard G, Pin JJ, Briere F, Trinchieri G (2003) Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol 171(12):6466–6477CrossRefPubMed

Zurück zum Zitat Huang M, Weiss WA (2013) Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 3(10):a014415CrossRefPubMedPubMedCentral Huang M, Weiss WA (2013) Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 3(10):a014415CrossRefPubMedPubMedCentral

Zurück zum Zitat Kroesen M, Brok IC, Reijnen D, van Hout-Kuijer MA, Zeelenberg IS, Den Brok MH, Hoogerbrugge PM, Adema GJ (2015) Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents. Cancer Immunol Immunother 64(5):563–572CrossRefPubMedPubMedCentral Kroesen M, Brok IC, Reijnen D, van Hout-Kuijer MA, Zeelenberg IS, Den Brok MH, Hoogerbrugge PM, Adema GJ (2015) Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents. Cancer Immunol Immunother 64(5):563–572CrossRefPubMedPubMedCentral

Zurück zum Zitat Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC (2012) Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 30(28):3525–3532CrossRefPubMedPubMedCentral Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC (2012) Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 30(28):3525–3532CrossRefPubMedPubMedCentral

Zurück zum Zitat Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Hakansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O’Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML (2011) Defining the critical hurdles in cancer immunotherapy. J Transl Med 9:214CrossRefPubMedPubMedCentral Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Hakansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O’Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML (2011) Defining the critical hurdles in cancer immunotherapy. J Transl Med 9:214CrossRefPubMedPubMedCentral

Zurück zum Zitat Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40(6):852–857CrossRefPubMed Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40(6):852–857CrossRefPubMed

Zurück zum Zitat Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI (2009) Subsets of myeloid-derived suppressor cells in tumor bearing mice. PMC 181(8):5791–5802 Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI (2009) Subsets of myeloid-derived suppressor cells in tumor bearing mice. PMC 181(8):5791–5802

Zurück zum Zitat Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16(11):2985–2995CrossRefPubMedPubMedCentral Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16(11):2985–2995CrossRefPubMedPubMedCentral

Zurück zum Zitat Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, Chesler L, Stallings RL (2011) miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. PLoS ONE 6(12):e28356CrossRefPubMedPubMedCentral Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, Chesler L, Stallings RL (2011) miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. PLoS ONE 6(12):e28356CrossRefPubMedPubMedCentral

Zurück zum Zitat Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, Haber M, Armati PJ, Weiss WA, Marshall GM (2004) Mechanisms of embryonal tumor initiation distinct roles for MycN expression and MYCN amplification. PNAS 101(34):12669CrossRef Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, Haber M, Armati PJ, Weiss WA, Marshall GM (2004) Mechanisms of embryonal tumor initiation distinct roles for MycN expression and MYCN amplification. PNAS 101(34):12669CrossRef

Zurück zum Zitat Moore HC, Wood KM, Jackson MS, Lastowska MA, Hall D, Imrie H, Redfern CP, Lovat PE, Ponthan F, O’Toole K, Lunec J, Tweddle DA (2008) Histological profile of tumours from MYCN transgenic mice. J Clin Pathol 61(10):1098–1103CrossRefPubMed Moore HC, Wood KM, Jackson MS, Lastowska MA, Hall D, Imrie H, Redfern CP, Lovat PE, Ponthan F, O’Toole K, Lunec J, Tweddle DA (2008) Histological profile of tumours from MYCN transgenic mice. J Clin Pathol 61(10):1098–1103CrossRefPubMed

Zurück zum Zitat Rasmuson A, Segerstrom L, Nethander M, Finnman J, Elfman LH, Javanmardi N, Nilsson S, Johnsen JI, Martinsson T, Kogner P (2012) Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS ONE 7(12):e51297CrossRefPubMedPubMedCentral Rasmuson A, Segerstrom L, Nethander M, Finnman J, Elfman LH, Javanmardi N, Nilsson S, Johnsen JI, Martinsson T, Kogner P (2012) Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS ONE 7(12):e51297CrossRefPubMedPubMedCentral

Zurück zum Zitat Kawakubo N, Harada Y, Ishii M, Souzaki R, Kinoshita Y, Tajiri T, Taguchi T, Yonemitsu Y (2018) Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression. Biochem Biophys Res Commun 503(3):1666–1673CrossRefPubMed Kawakubo N, Harada Y, Ishii M, Souzaki R, Kinoshita Y, Tajiri T, Taguchi T, Yonemitsu Y (2018) Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression. Biochem Biophys Res Commun 503(3):1666–1673CrossRefPubMed

Zurück zum Zitat Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R (2016) Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin Cancer Res 22(15):3849–3859CrossRefPubMed Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R (2016) Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin Cancer Res 22(15):3849–3859CrossRefPubMed

Zurück zum Zitat Haraguchi S, Nakagawara A (2009) A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse. PLoS ONE 4(9):e6902CrossRefPubMedPubMedCentral Haraguchi S, Nakagawara A (2009) A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse. PLoS ONE 4(9):e6902CrossRefPubMedPubMedCentral

Zurück zum Zitat Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, Tong Z, Tan S, Zhang H, Saw PE, Gu Y, Wang J, Zhang Y, Shang L, Liu Y, Jiang S, Yan B, Li R, Yang Y, Yu J, Chen Y, Gao GF, Ye Q, Gao S (2020) Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci U S A 117(12):6640–6650CrossRefPubMedPubMedCentral Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, Tong Z, Tan S, Zhang H, Saw PE, Gu Y, Wang J, Zhang Y, Shang L, Liu Y, Jiang S, Yan B, Li R, Yang Y, Yu J, Chen Y, Gao GF, Ye Q, Gao S (2020) Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci U S A 117(12):6640–6650CrossRefPubMedPubMedCentral

Zurück zum Zitat Yao H, Wang H, Li C, Fang J-Y, Xu J (2018) Cancer cell-intrinsic pd-1 and implications in combinatorial immunotherapy. Front Immunol. https://doi.org/10.3389/fimmu.2018.01774CrossRefPubMedPubMedCentral Yao H, Wang H, Li C, Fang J-Y, Xu J (2018) Cancer cell-intrinsic pd-1 and implications in combinatorial immunotherapy. Front Immunol. https://​doi.​org/​10.​3389/​fimmu.​2018.​01774CrossRefPubMedPubMedCentral

Zurück zum Zitat Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel BR, Santi M, Merchant MS, Geoerger B, Hezam I, Marty V, Vielh P, Daugaard M, Sorensen PH, Mackall CL, Maris JM (2017) Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer 123(19):3807–3815CrossRefPubMed Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel BR, Santi M, Merchant MS, Geoerger B, Hezam I, Marty V, Vielh P, Daugaard M, Sorensen PH, Mackall CL, Maris JM (2017) Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer 123(19):3807–3815CrossRefPubMed

Zurück zum Zitat Aoki T, Hino M, Koh K, Kyushiki M, Kishimoto H, Arakawa Y, Hanada R, Kawashima H, Kurihara J, Shimojo N, Motohashi S (2016) Low frequency of programmed death ligand 1 expression in pediatric cancers. Pediatr Blood Cancer 63(8):1461–1464CrossRefPubMedPubMedCentral Aoki T, Hino M, Koh K, Kyushiki M, Kishimoto H, Arakawa Y, Hanada R, Kawashima H, Kurihara J, Shimojo N, Motohashi S (2016) Low frequency of programmed death ligand 1 expression in pediatric cancers. Pediatr Blood Cancer 63(8):1461–1464CrossRefPubMedPubMedCentral

Zurück zum Zitat Moreno-Vicente J, Beers SA, Gray JC (2019) PD-1/PD-L1 blockade in paediatric cancers: what does the future hold? Cancer Lett 457:74–85CrossRefPubMed Moreno-Vicente J, Beers SA, Gray JC (2019) PD-1/PD-L1 blockade in paediatric cancers: what does the future hold? Cancer Lett 457:74–85CrossRefPubMed

Zurück zum Zitat Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL (2020) Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol 21(4):541–550CrossRefPubMedPubMedCentral Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL (2020) Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol 21(4):541–550CrossRefPubMedPubMedCentral

Zurück zum Zitat Ehlert K, Hansjuergens I, Zinke A, Otto S, Siebert N, Henze G, Lode H (2020) Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma. J Immunother Cancer 8(1):540CrossRef Ehlert K, Hansjuergens I, Zinke A, Otto S, Siebert N, Henze G, Lode H (2020) Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma. J Immunother Cancer 8(1):540CrossRef

Zurück zum Zitat Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC Jr, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T (2015) Melanoma cell-intrinsic pd-1 receptor functions promote tumor growth. Cell 162(6):1242–1256CrossRefPubMedPubMedCentral Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC Jr, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T (2015) Melanoma cell-intrinsic pd-1 receptor functions promote tumor growth. Cell 162(6):1242–1256CrossRefPubMedPubMedCentral

Zurück zum Zitat Li H, Li X, Liu S, Guo L, Zhang B, Zhang J, Ye Q (2017) Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology 66(6):1920–1933CrossRefPubMed Li H, Li X, Liu S, Guo L, Zhang B, Zhang J, Ye Q (2017) Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology 66(6):1920–1933CrossRefPubMed

Zurück zum Zitat Du S, McCall N, Park K, Guan Q, Fontina P, Ertel A, Zhan T, Dicker AP, Lu B (2018) Blockade of tumor-expressed pd-1 promotes lung cancer growth. Oncoimmunology 7(4):e1408747CrossRefPubMedPubMedCentral Du S, McCall N, Park K, Guan Q, Fontina P, Ertel A, Zhan T, Dicker AP, Lu B (2018) Blockade of tumor-expressed pd-1 promotes lung cancer growth. Oncoimmunology 7(4):e1408747CrossRefPubMedPubMedCentral